To increase external validity, we propose that future trials follow the BNP inclusion criterion as used in the PARADIGM‐HF trial involving sacubitril/valsartan, rather than include trial participants based on an acute HF‐related hospital admission.49, 50. Here, NPPB is linked to hydrops fetalis.